Paul L Berns - Net Worth and Insider Trading

Paul L Berns Net Worth

The estimated net worth of Paul L Berns is at least $384 Million dollars as of 2025-07-22. Paul L Berns is the Director of Metsera Inc and owns about 9,271,239 shares of Metsera Inc (MTSR) stock worth over $366 Million. Paul L Berns is the See Remarks of Neumora Therapeutics Inc and owns about 7,804,295 shares of Neumora Therapeutics Inc (NMRA) stock worth over $15 Million. Paul L Berns is also the President and CEO of Anacor Pharmaceuticals Inc and owns about 230,311 shares of Anacor Pharmaceuticals Inc (ANAC) stock worth over $2 Million. Besides these, Paul L Berns also holds Jazz Pharmaceuticals PLC (JAZZ) , Cellectar Biosciences Inc (CLRB) . Details can be seen in Paul L Berns's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Paul L Berns has not made any transactions after 2025-02-18 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data
Unlimited Filters in All-in-One Stock Screener
Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Quick Customer Support
And Much More...

Transaction Summary of Paul L Berns

To

Paul L Berns Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Paul L Berns owns 8 companies in total, including Jazz Pharmaceuticals PLC (JAZZ) , Unity Biotechnology Inc (UNBX) , and VYNE Therapeutics Inc (VYNE) among others .

Click here to see the complete history of Paul L Berns’s form 4 insider trades.

Insider Ownership Summary of Paul L Berns

Ticker Company Transaction Date Type of Owner
JAZZ Jazz Pharmaceuticals PLC 2021-08-05 director
UNBX Unity Biotechnology Inc 2020-06-18 director
VYNE VYNE Therapeutics Inc 2019-06-25 director
LIMIT LIMIT 2016-06-24 director & President and CEO
LIMIT LIMIT 2016-05-17 director
LIMIT LIMIT 2016-04-20 director
LIMIT LIMIT 2021-12-17 director
LIMIT LIMIT 2025-02-18 director

Paul L Berns Latest Holdings Summary

Paul L Berns currently owns a total of 5 stocks. Among these stocks, Paul L Berns owns 9,271,239 shares of Metsera Inc (MTSR) as of February 3, 2025, with a value of $366 Million and a weighting of 95.32%. Paul L Berns owns 7,804,295 shares of Neumora Therapeutics Inc (NMRA) as of February 18, 2025, with a value of $15 Million and a weighting of 3.84%. Paul L Berns also owns 230,311 shares of Anacor Pharmaceuticals Inc (ANAC) as of March 22, 2016, with a value of $2 Million and a weighting of 0.59%. The other 2 stocks Jazz Pharmaceuticals PLC (JAZZ) , Cellectar Biosciences Inc (CLRB) have a combined weighting of 0.25% among all his current holdings.

Latest Holdings of Paul L Berns

Ticker Company Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
MTSR Metsera Inc 2025-02-03 9,271,239 39.45 365,750,379
NMRA Neumora Therapeutics Inc 2025-02-18 7,804,295 1.89 14,750,118
ANAC Anacor Pharmaceuticals Inc 2016-03-22 230,311 9.82 2,261,654
JAZZ Jazz Pharmaceuticals PLC 2021-08-05 8,290 116.34 964,459
CLRB Cellectar Biosciences Inc 2016-04-20 39 5.20 203

Holding Weightings of Paul L Berns


Paul L Berns Form 4 Trading Tracker

According to the SEC Form 4 filings, Paul L Berns has made a total of 1 transactions in Metsera Inc (MTSR) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Metsera Inc is the acquisition of 789,998 shares on February 3, 2025, which cost Paul L Berns around $14 Million.

According to the SEC Form 4 filings, Paul L Berns has made a total of 1 transactions in Neumora Therapeutics Inc (NMRA) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Neumora Therapeutics Inc is the sale of 13,871 shares on February 18, 2025, which brought Paul L Berns around $23,442.

According to the SEC Form 4 filings, Paul L Berns has made a total of 0 transactions in Anacor Pharmaceuticals Inc (ANAC) over the past 5 years. The most-recent trade in Anacor Pharmaceuticals Inc is the sale of 37,500 shares on March 22, 2016, which brought Paul L Berns around $2 Million.

More details on Paul L Berns's insider transactions can be found in the Insider Trading History of Paul L Berns table.

Insider Trading History of Paul L Berns

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Paul L Berns Trading Performance

GuruFocus tracks the stock performance after each of Paul L Berns's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Paul L Berns is 8.82%. GuruFocus also compares Paul L Berns's trading performance to market benchmark return within the same time period. The performance of stocks bought by Paul L Berns within 3 months outperforms 1 times out of 2 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Paul L Berns's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Paul L Berns

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
1 out of 1 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 35.41 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 37.81 LIMIT LIMIT LIMIT LIMIT LIMIT

Paul L Berns Ownership Network

Ownership Network List of Paul L Berns

No Data

Ownership Network Relation of Paul L Berns

Insider Network Chart


Paul L Berns Owned Company Details

What does Jazz Pharmaceuticals PLC do?

Who are the key executives at Jazz Pharmaceuticals PLC?

Paul L Berns is the director of Jazz Pharmaceuticals PLC. Other key executives at Jazz Pharmaceuticals PLC include director & Executive Chairman Bruce C Cozadd , VP & Finance& PAO Patricia Carr , and EVP & Research & Development Robert Iannone .

Jazz Pharmaceuticals PLC (JAZZ) Insider Trades Summary

Over the past 18 months, Paul L Berns made no insider transaction in Jazz Pharmaceuticals PLC (JAZZ). Other recent insider transactions involving Jazz Pharmaceuticals PLC (JAZZ) include a net sale of 17,500 shares made by Bruce C Cozadd , a net sale of 10,646 shares made by Patricia Carr , and a net sale of 12,500 shares made by Neena M Patil .

In summary, during the past 3 months, insiders sold 3,500 shares of Jazz Pharmaceuticals PLC (JAZZ) in total and bought 101,621 shares, with a net purchase of 98,121 shares. During the past 18 months, 51,539 shares of Jazz Pharmaceuticals PLC (JAZZ) were sold and 113,621 shares were bought by its insiders, resulting in a net purchase of 62,082 shares.

Jazz Pharmaceuticals PLC (JAZZ)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Jazz Pharmaceuticals PLC Insider Transactions

No Available Data

Paul L Berns Mailing Address

Above is the net worth, insider trading, and ownership report for Paul L Berns. Based on the public information released on the U.S. Securities and Exchange Commission (SEC) website, Paul L Berns's mailing address is: Westminster Co 80020.